CD44 and HAP‐Conjugated hADSCs as Living Materials for Targeted Tumor Therapy and Bone Regeneration

He, Xiao; Hao, Min; Li, Kaiwen; Chen, Xin; Yu, Liyang; Qiu, Jichuan; Zhang, Hongyu; Li, Haijun; Sang, Yuanhua; Li, Hong

doi:10.1002/advs.202206393

Cited by 5 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Robust evidence supports that antitumor agents conjugated by biomaterials show good antitumor effects and targeting activity through a ligand–receptor‐mediated targeting mechanism. 283 , 284 , 285 For instance, CS‐conjugated doxorubicin poly(lactic‐co‐glycolic acid) (PLGA) nanoparticles were found to directly target CD44 with low cardiac toxicity and strong antitumor ability. 286 Moreover, an HA‐labeled PLGA nanoparticle encapsulating both paclitaxel and focal adhesion kinase siRNA was reported to bind to CD44‐positive epithelial ovarian cancer cells to overcome chemoresistance.…”

Section: Anticancer Therapeutic Strategies Based On Targeting Cd44mentioning

confidence: 99%

CD44 and its implication in neoplastic diseases

Xu,

Bai,

Lan

et al. 2024

MedComm

View full text Add to dashboard Cite

CD44, a nonkinase single span transmembrane glycoprotein, is a major cell surface receptor for many other extracellular matrix components as well as classic markers of cancer stem cells and immune cells. Through alternative splicing of CD44 gene, CD44 is divided into two isoforms, the standard isoform of CD44 (CD44s) and the variant isoform of CD44 (CD44v). Different isoforms of CD44 participate in regulating various signaling pathways, modulating cancer proliferation, invasion, metastasis, and drug resistance, with its aberrant expression and dysregulation contributing to tumor initiation and progression. However, CD44s and CD44v play overlapping or contradictory roles in tumor initiation and progression, which is not fully understood. Herein, we discuss the present understanding of the functional and structural roles of CD44 in the pathogenic mechanism of multiple cancers. The regulation functions of CD44 in cancers‐associated signaling pathways is summarized. Moreover, we provide an overview of the anticancer therapeutic strategies that targeting CD44 and preclinical and clinical trials evaluating the pharmacokinetics, efficacy, and drug‐related toxicity about CD44‐targeted therapies. This review provides up‐to‐date information about the roles of CD44 in neoplastic diseases, which may open new perspectives in the field of cancer treatment through targeting CD44.

show abstract

Section: Anticancer Therapeutic Strategies Based On Targeting Cd44mentioning

confidence: 99%

CD44 and its implication in neoplastic diseases

Xu,

Bai,

Lan

et al. 2024

MedComm

View full text Add to dashboard Cite

show abstract

Biosensor‐Based Microfluidic Platforms for Rapid Clinical Detection of Pathogenic Bacteria

Hou,

Liu,

Huang

et al. 2024

Adv Funct Materials

View full text Add to dashboard Cite

Pathogenic bacteria are commonly found in food, water, and soil, posing significant public health challenges globally. Therefore, early, rapid, and highly sensitive strategies for monitoring the bacterial proliferation are crucial for ensuring public health, medical diagnosis, and food safety. Compared to traditional techniques, microfluidic platforms provide powerful detective tools characterized by high integration, high throughput, ease of operation, low reagent consumption, and high sensitivity. Driven by substantial commercial demand, research and development in microfluidic‐based rapid detection methods and technologies has progressed significantly derived by the interdisciplinary integration of multiple disciplines. In this review, progress in clinical detection of pathogenic bacteria with microfluidic biosensors, including microfluidic devices for point‐of‐care (POC) testing, is summarized. Strategies for pathogenic bacteria detection, containing their advantages and disadvantages are discussed in detail. Advanced platforms for capturing and detecting pathogenic bacteria, such as microchannels, microarrays, digital microfluidics (DMF) and paper‐based platforms, are highlighted. The accomplishments and shortcomings of these microfluidic devices are also summarized. Additionally, case studies of biosensor‑based microfluidic devices used for detecting diseases caused by bacterial imbalances are listed. Finally, possible research perspectives for further development in highly effective biosensor‑based microfluidics for clinical detection of pathogenic bacteria are proposed.

show abstract

CD44 and HAP‐Conjugated hADSCs as Living Materials for Targeted Tumor Therapy and Bone Regeneration

Hao

et al. 2023

Advanced Science

Self Cite

View full text Add to dashboard Cite

Combining targeted tumor therapy with tissue regeneration represents a promising strategy for synergistic tumor therapy. In this study, a multifunctional living material is constructed with human‐derived adipose stem cells (hADSCs) and antibody‐modified hydroxyapatite nanorods (nHAP) for targeted drug delivery and bone regeneration following surgery. The living material delivers the therapeutics to the tumor site efficiently based on the strength of the inherent tumor tropism of hADSCs. The bioconjugation of nHAP with hADSCs via specific antibody modification is found to be biocompatible, even when loaded with the chemotherapeutic drug doxorubicin (Dox). The endocytosis of nHAP stimulates the osteogenic differentiation of hADSCs, promoting bone tissue regeneration. Moreover, the antibody‐modified nHAP‐hADSC conjugate exhibits targeted tumor delivery, which is further facilitated by pH‐triggered release of Dox, inducing apoptosis of tumor cells with low toxicity to healthy tissues. Therefore, the present study provides a general strategy for engineering living materials to achieve targeted tumor therapy and bone tissue regeneration after surgery, which can be extended to other disease types.

show abstract

CD44 and HAP‐Conjugated hADSCs as Living Materials for Targeted Tumor Therapy and Bone Regeneration

Cited by 5 publications

References 38 publications

CD44 and its implication in neoplastic diseases

CD44 and its implication in neoplastic diseases

Biosensor‐Based Microfluidic Platforms for Rapid Clinical Detection of Pathogenic Bacteria

CD44 and HAP‐Conjugated hADSCs as Living Materials for Targeted Tumor Therapy and Bone Regeneration

Contact Info

Product

Resources

About